Karl D. Lewis

Regeneron (United States) — United States

Medicine · Health Sciences

62h-index27.9kcitations349works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(124), Melanoma and MAPK Pathways(118), CAR-T cell therapy research(90), Immunotherapy and Immune Responses(64), Cutaneous Melanoma Detection and Management(56)

Publications347 total

Supplementary table 4 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
Supplementary table 1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
Supplementary table 2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
Supplementary Figure S1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
Supplementary Figure S2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
Supplementary table 3 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
Supplementary Table 5 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
2025Open Access
1632P Predicting real-world overall survival in advanced melanoma using machine learning
Annals of Oncology·2025
Utilizing the EORTC Item Library to develop a tailored patient-reported outcome measure (PROM; CSCC-NAAP-32) to evaluate quality of life in resectable advanced (RA) cutaneous squamous cell carcinoma (CSCC).
Journal of Clinical Oncology·2025
A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.
Journal of Clinical Oncology·2025· 2 cited
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis
Future Oncology·2025Open Access
Abstract LB366: Fianlimab + cemiplimab in patients (pts) with advanced (adv) melanoma (Mel): Subgroup analyses by blinded independent central review (BICR)
Cancer Research·2025
Fianlimab + cemiplimab in patients with advanced melanoma: Subgroup analyses by blinded independent central review (BICR)
EJC Skin Cancer·2025Open Access
A Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic melanoma
EJC Skin Cancer·2025· 1 citedOpen Access
Analytical Quality Evaluation of the Tox21 Compound Library
Chemical Research in Toxicology·2024· 8 citedOpen Access
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Journal for ImmunoTherapy of Cancer·2024· 23 citedOpen Access
489 An early phase expansion cohort study of fianlimab (anti–lymphocyte activation gene-3 [LAG-3]) plus cemiplimab (anti–programmed cell death-1 [PD-1]) in patients with advanced malignancies
Regular and Young Investigator Award Abstracts·2024Open Access
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
Journal of the American Academy of Dermatology·2024· 41 cited
1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment
Annals of Oncology·2024Open Access
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial
Future Oncology·2024Open Access
page 1 of 18Next →

Frequent Co-authors

René González(21), Omid Hamid(14), Igor Puzanov(11), Anne Lynn S. Chang(11), Ragini R. Kudchadkar(10), Michael R. Migden(10), Jeffrey A. Sosman(9), Axel Hauschild(9), Anna C. Pavlick(8), Alexander Guminski(8), William A. Robinson(8), Keith T. Flaherty(7), Adil Daud(7), Kevin B. Kim(7), Jeffrey S. Weber(7), Reinhard Dummer(7), Dirk Schadendorf(7), Nikhil I. Khushalani(7), Alain P. Algazi(6), Georgina V. Long(6)